专利号:US-2025109170-A1 优先权日:2021-12-01 标 题 :Method for manufacturing ganirelix 发明人:KIM JAE IL; HWANG KOOK SANG; LEE JU YOUNG; KIM DONG MIN; JO EUN JIN; LEE SEUL GI 权利人:ANYGEN CO LTD 摘要:In a method for manufacturing ganirelix, a peptide intermediate A represented by Chemical Formula 19 is obtained, a peptide intermediate B represented by Chemical Formula 21 is obtained, and ganirelix represented by Chemical Formula 13 is obtained through a convergent synthesis of the peptide intermediate A and the peptide intermediate B. Ganirelix can be obtained in high purity and high yield, and the commercial mass-production process therefor is feasible, and also, an economical advantage, that is, the reduction in the production costs compared to conventional technologies, is provided. Furthermore, it is possible to obtain a large quantity of Ganirelix more safely than conventional technologies.
[参考文献]: Martyna Kielmas, Et Al. Comparison Of Modification Sites In Glycated Crystallin In Vitro And In Vivo. Anal Bioanal Chem. 2015 Mar;407(9):2557-67.
合成参考文献
参考文献:10.1007/bf02576873|10.1023/a:1024140900571 摘要:Sabatino G, Mulinacci B, Alcaro MC, Chelli M, Rovero P, Papini AM. Assessment of new 6-Cl-HOBt based coupling reagents for peptide synthesis. Part 1: Coupling efficiency study. International Journal of Peptide Research and Therapeutics. 2002 Mar;9(2-3):119–23. doi: 10.1023/a:1024140900571.